研究者詳細 - 光井　崇

論文 - 光井　崇

分割表示 251 件中 61 - 80 件目／全件表示 >>

妊娠高血圧症候群の母体より出生した児の3歳までの身体発育の調査 SGA児の発育への影響因子の検討

光井崇, 三島桜子, 谷和祐, 増山寿

現代産婦人科 69 ( Suppl. ) S26 - S26 2021年9月

母体骨形成不全症合併妊娠の1症例

谷岡桃子, 樫野千明, 横畑理美, 久保光太郎, 長谷川徹, 光井崇, 衛藤英理子, 鎌田泰彦, 中塚幹也, 増山寿

現代産婦人科 69 ( Suppl. ) S64 - S65 2021年9月

妊娠高血圧症候群の母体より出生した児の3歳までの身体発育の調査 SGA児の発育への影響因子の検討

光井崇, 三島桜子, 谷和祐, 増山寿

現代産婦人科 69 ( Suppl. ) S26 - S26 2021年9月

腹腔鏡下に予防的性腺摘出術を施行した完全型アンドロゲン不応症(complete androgen insensitivity syndrome、CAIS)の1例

篠崎真里奈, 久保光太郎, 樫野千明, 光井崇, 長谷川徹, 鎌田泰彦, 中塚幹也, 増山寿

現代産婦人科 69 ( Suppl. ) S88 - S88 2021年9月

母体骨形成不全症合併妊娠の1症例

谷岡桃子, 樫野千明, 横畑理美, 久保光太郎, 長谷川徹, 光井崇, 衛藤英理子, 鎌田泰彦, 中塚幹也, 増山寿

現代産婦人科 69 ( Suppl. ) S64 - S65 2021年9月

月経直後の子宮ファイバースコピー所見と病理組織学的な慢性子宮内膜炎診断との関連

澤井雄大, 光井崇, 樫野千明, 久保光太郎, 長谷川徹, 鎌田泰彦, 中塚幹也, 増山寿

現代産婦人科 69 ( Suppl. ) S86 - S87 2021年9月

直腸壁全層に及ぶ腸管子宮内膜症に対し、TaTME(経肛門的全直腸間膜切除術)を併用し腹腔鏡下に根治術を施行した一例

岡本和浩, 鎌田泰彦, 許春花, 樫野千明, 松岡敬典, 依田尚之, 光井崇, 久保光太郎, 小川千加子, 中村圭一郎, 増山寿

日本産科婦人科内視鏡学会雑誌 37 ( Suppl.I ) 281 - 281 2021年9月

Clinical Course of 60 Cesarean Scar Pregnancies.

Takashi Mitsui, Sakurako Mishima, Kazumasa Tani, Jota Maki, Eriko Eto, Kei Hayata, Hisashi Masuyama

Acta medica Okayama 75 ( 4 ) 439 - 445 2021年8月

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）

Early diagnosis and therapy are important in a cesarean scar pregnancy (CSP), which can cause uterine rupture with resultant massive bleeding. However, there are some reports of CSPs continued to term. The optimal management of CSPs remains unclear; therefore, we investigated the clinical courses of CSPs diagnosed and treated at perinatal institutions in the Chugoku and Shikoku regions of Japan. We enrolled 60 women diag-nosed with CSP at 21 institutions from January 2006 to December 2015. Of the 60 women diagnosed with CSP, 57 were treated. Pregnancy was terminated in 48 women and continued in 9. Thirteen women underwent transabdominal hysterectomy; they experienced no postoperative complications or allogeneic blood transfu-sion. Nine women received therapies such as dilation and curettage, and 26 received non-surgical therapies such as methotrexate and topical administration of potassium chloride. Among 9 women who chose to con-tinue with their CSP, 7 successfully delivered newborns, 2 had uterine ruptures in the second trimester, and all women required transabdominal hysterectomy. Diagnosis and therapy in the first trimester of pregnancy are important in the management strategy of a CSP. When continuing a CSP, the risk of uterine rupture and trans-abdominal hysterectomy must be considered.

DOI： 10.18926/AMO/62395

PubMed

researchmap

妊娠高血圧症候群の母体から生まれた児の3歳までの身体発育に関する調査子宮内発育遅延児の発育に影響を及ぼす因子の検討(A survey on physical development up to the third year of life in offspring born to mothers with hypertensive disorders of pregnancy: Examination of factors influencing the development of small-for-gestational-age offspring)

Mishima Sakurako, Mitsui Takashi, Tani Kazumasa, Oohira Akiko, Maki Jota, Eto Eriko, Hayata Kei, Narai Yoko, Honda Tetsurou, Kai Kenji, Tada Katsuhiko, Harada Takashi, Maeda Kazuhisa, Nagai Ryuhei, Shimoya Koichiro, Abe Emiko, Matsubara Yuko, Murata Susumu, Miyoshi Hiroshi, Masuyama Hisashi

The Journal of Obstetrics and Gynaecology Research 47 ( 8 ) 2866 - 2866 2021年8月

ヒト絨毛細胞の浸潤におけるPROKR2を介したEG-VEGFの役割(The role of EG-VEGF through PROKR2 in the invasion of human trophoblast cells)

Tani Kazumasa, Mitsui Takashi, Mishima Sakurako, Oohira Akiko, Maki Jota, Eto Eriko, Hayata Kei, Nakamura Keiichiro, Masuyama Hisashi

The Journal of Obstetrics and Gynaecology Research 47 ( 8 ) 2829 - 2829 2021年8月

過去10年間に37週以降で分娩となった母体における低出生体重児のリスク因子の変遷査読

假谷奈生子, 光井崇, 三島桜子, 大平安希子, 谷和祐, 牧尉太, 衛藤英理子, 早田桂, 増山寿

現代産婦人科 69 ( 2 ) 213 - 218 2021年6月

妊娠高血圧症候群の母体より出生したSGA児のcatch-upに影響する因子

三島桜子, 光井崇, 三苫智裕, 横畑理美, 大平安希子, 谷和祐, 牧尉太, 衛藤英理子, 早田桂, 鷲尾洋介, 吉本順子, 塚原宏一, 増山寿

日本周産期・新生児医学会雑誌 57 ( Suppl. ) P218 - P218 2021年6月

院内発症の死戦期帝王切開と院外発症の死戦期帝王切開を経験して

三苫智裕, 早田桂, 横畑理美, 三島桜子, 大平安希子, 谷和祐, 牧尉太, 光井崇, 衛藤英理子, 増山寿

日本周産期・新生児医学会雑誌 57 ( Suppl. ) P267 - P267 2021年6月

妊娠高血圧症の母親から生まれた児における3歳の肥満有病率および関連リスク因子

光井崇, 谷和祐, 三島桜子, 鷲尾洋介, 吉本順子, 塚原宏一, 増山寿

日本周産期・新生児医学会雑誌 57 ( Suppl. ) P158 - P158 2021年6月

広汎子宮頸部摘出術から10年の経過で妊娠し、産後に晩期再発した一例

石橋めぐみ, 花岡有為子, 鎌田恭輔, 香西亜優美, 山本健太, 天雲千晶, 伊藤恵, 新田絵美子, 森信博, 田中宏和, 金西賢治, 光井崇, 増山寿

日本周産期・新生児医学会雑誌 57 ( Suppl. ) P237 - P237 2021年6月

hCG values and gestational sac size as indicators of successful systemic methotrexate treatment in cesarean scar pregnancy 国際誌

Takashi Mitsui, Sakurako Mishima, Akiko Ohira, Kazumasa Tani, Jota Maki, Eriko Eto, Kei Hayata, Hisashi Masuyama

Taiwanese Journal of Obstetrics and Gynecology 60 ( 3 ) 454 - 457 2021年5月

担当区分：筆頭著者記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Elsevier BV

OBJECTIVE: To retrospectively investigate cesarean scar pregnancy (CSP) patients who received systemic methotrexate (MTX) and to clarify the criteria for administering systemic MTX to CSP patients. MATERIALS AND METHODS: Fifteen CSP patients who were initially treated with systemic MTX (50 mg/m2/week) were included. Nine patients, who needed a uterine artery embolization (UAE) or a laparotomy, including a transabdominal hysterectomy (TAH), were defined as the unsuccessful MTX group. Six patients who did not require UAE or a laparotomy were defined as the successful MTX group. Furthermore, the hCG cut-off value and the GS cut-off size at the time of CSP diagnosis, which differentiated successful and unsuccessful patients, were defined. MTX success rates were investigated by combining the hCG and gestational sac (GS) size cut-off values. RESULTS: The hCG cut-off value was 17757.0 mIU/mL, and the GS cut-off size was 10.4 mm. In patients with hCG values less than 17757.0 mIU/mL, the MTX success rate was 75.0%. Fewer patients needed UAE or a laparotomy compared to patients with hCG values higher than 17757.0 mIU/mL (P = 0.007). In patients with a GS size less than 10.4 mm, the MTX success rate was 80.0%. Fewer patients among them needed UAE or a laparotomy compared to those among patients with a GS size greater than 10.4 mm (P = 0.089). In patients with hCG values and GS sizes lower than the cut-off values, the MTX success rate was 80.0%. Fewer patients among them needed UAE or a laparotomy compared to those among patients with hCG values and/or GS sizes higher than the cut-off values, respectively (P = 0.010). CONCLUSION: Patients with hCG values less than 17757.0 mIU/mL and GS sizes less than 10.4 mm may have a greater chance of successful systemic MTX treatment when it is used as the first line of treatment for CSP.

DOI： 10.1016/j.tjog.2021.03.011

PubMed

researchmap

視床下部性無月経と甲状腺機能低下症を呈した同胞例

光井崇, 楠元理恵, 樫野千明, 久保光太郎, 鎌田泰彦, 増山寿

日本内分泌学会雑誌 97 ( 1 ) 362 - 362 2021年4月